Скачайте изображение (превью) выбрав качество

320x180 480x360 640x480 1280x720

Watch on Radcliffe Cardiology: *1ymyha0*_ga*MTMwMzM0NDE5OC4xNjQ0ODQ4MDk3*_ga_T874FCJ3LG*MTY2NjE3NjU4MC4zMzkuMC4xNjY2MTc2NTgxLjAuMC4w

Dr Ambarish Pandey (UT Southwestern Medical Center, US) talks about the post-hoc analyses of VERTIS CV trial.
In VERTIS CV, an SGLT2 inhibitor, ertugliflozin (Merck Sharp & Dohme LLC) reduced risk of hospitalization for heart failure compared with placebo. This post-hoc analyses investigated the efficacy of the treatment across the spectrum of ejection fractions (EF) in heart failure.

Questions
1. What is the background of this analysis?
2. What was the study design and patient population?
3. What are the key findings and how are these compare to existing evidence?
4. What further research required?

Recorded remotely from Dallas, 2022.

Interviewer: Mirjam Boros
Videographer: Dan Brent
This content is intended for healthcare professionals only.

Radcliffe brings medical knowledge, insight and innovation to life for CV clinicians around the world, using our communications & creative expertise, our platforms and connections across the community to help transform theory into practice faster.

Чтобы скачать видео "EASD 2022: Efficacy of Ertugliflozin HHF Across the Spectrum of Pre-Trial EF | Dr Ambarish Pandey" передвинте ползунок вправо